Faits intéressants

• Lundbeck Gains Amid Speculation of Antidepressant Success - Bloomberg
  

  Lundbeck Gains Amid Speculation of Antidepressant SuccessBloombergH.

• Mylan 1Q profit rises on Lexapro and EpiPen sales - BusinessWeek
  

  Mylan 1Q profit rises on Lexapro and EpiPen salesBusinessWeekGeneric drugmaker Mylan Inc.

• Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarter - The Pharma Letter
  

  Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarterThe Pharma LetterEBIT fell 32% to 882 million kroner, also shy of analysts' expectations of 895 million kroner, as the company faced generic competition for its flagship antidepressant Cipralex/Lexapro (escitalopram), which is sold by Forest Labs in the USA.

• Lundbeck buoyed by data on new antidepressant - PMLiVE
  

  Lundbeck buoyed by data on new antidepressantPMLiVELundbeck has reported positive phase III data on LU AA21004, a new antidepressant that could help it cope with the impact of generic competition to flagship product Cipralex/Lexapro.

• Mother of slain teen again assailed under cross examination - Evansville Courier & Press
  

  Mother of slain teen again assailed under cross examinationEvansville Courier & PressThose records showed Jessica Oesterle had been diagnosed with major depressive disorder and bipolar disorder at different times, and included a statement by her from May 2009 that the depression medicine Lexapro had been giving her homicidal thoughts.